<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002596</url>
  </required_header>
  <id_info>
    <org_study_id>PD001J</org_study_id>
    <nct_id>NCT04002596</nct_id>
  </id_info>
  <brief_title>Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease</brief_title>
  <acronym>TDPD</acronym>
  <official_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness in ExAblate Neuro treatment of medication-refractory tremor in&#xD;
      subjects with idiopathic Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this prospective, single-arm, multi-site, feasibility study is to develop data to&#xD;
      evaluate the safety and effectiveness of unilateral focused ultrasound thalamotomy using this&#xD;
      ExAblate Transcranial System in the treatment of medication-refractory tremor resulting from&#xD;
      idiopathic Parkinson's disease.&#xD;
&#xD;
      The Indications for Use claim for this system is: treatment of medication-refractory tremor&#xD;
      in subjects with idiopathic Parkinson's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ExAblate Neuro Treatment Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Rating Scale for Tremor</measure>
    <time_frame>3 Months after Treatment</time_frame>
    <description>Primary effectiveness will be a comparison of the CRST scores at baseline vs. 3 months. (Range 0-152, scores are combined, the higher the score, the greater the clinical level of tremor, the worse clinical outcome is)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Device and Procedure related complications</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor dominant PD after the ExAblate treatment and during the follow-up period of up up to 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Rating Scale for Tremor, Total Score</measure>
    <time_frame>1 year</time_frame>
    <description>On-medication, total tremor (CRST) score (Range 0-152, scores are combined, the higher the score, the greater the clinical level of tremor, the worse clinical outcome is)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Rating Scale for Tremor, Part C</measure>
    <time_frame>1 year</time_frame>
    <description>Level of disability measured from Part C subsection of CRST - Subcore of sections 16 to 23 (Range 0-32, scores are combined, the higher the scub-score, the greater the level of subject's disability, the worse clinical outcome is)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire - 39</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life assessment with PDQ-39 (Range 0-156, scores are combined, the higher the score, the greater the level of clinical expression of Parkinson Disease, the worse clinical outcome is)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>ExAblate MRgFUS treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate Neuro Thalamotomy Treatment</intervention_name>
    <description>Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease</description>
    <arm_group_label>ExAblate MRgFUS treatment</arm_group_label>
    <other_name>MRgFUS Vim ablation</other_name>
    <other_name>Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, age 30 years and older&#xD;
&#xD;
          2. Subjects who are able and willing to give informed consent and able to attend all&#xD;
             study visits through 3 Months&#xD;
&#xD;
          3. Subjects with a diagnosis of idiopathic PD as confirmed from clinical history and&#xD;
             examination by a movement disorder neurologist at the site&#xD;
&#xD;
          4. All subjects included in this study will have a TD/PIGD ratio &gt; 1.15 in the medicated&#xD;
             [ON] state as calculated from the UPDRS formula as described by S, et. al., [74].&#xD;
&#xD;
             Note: Ratios for TD/PIGD that are greater than or equal to 1.15 are defined as TDPD.&#xD;
             PIGD includes those with a ratio of less than or equal to 0.9. Scores of greater than&#xD;
             0.9 and less than 1.15 are considered a mixed subtype.&#xD;
&#xD;
          5. Subject demonstrates a resting tremor severity score of greater than or equal to 3 in&#xD;
             the hand/arm as measured by the medicated (ON) MDS-UPDRS question 3.17 or a&#xD;
             postural/action tremor greater than or equal to a 2 for question 3.15 or 3.16.&#xD;
&#xD;
          6. Significant disability due to PD tremor despite medical treatment (CRST score of 2 or&#xD;
             above in any one of the items 16-23 from the Disability subsection of the CRST:&#xD;
             [speaking, feeding other than liquids, bringing liquids to mouth, hygiene, dressing,&#xD;
             writing, working, and social activities])&#xD;
&#xD;
          7. Tremor remains disabling when medical therapy is optimal or not tolerated for the&#xD;
             treatment of other cardinal signs of PD (bradykinesia, rigidity, etc), as determined&#xD;
             by a movement disorders neurologist at the site&#xD;
&#xD;
          8. Subjects should be on a stable dose of all PD medications for 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          9. The thalamus must be apparent on MRI such that targeting of the Vim nucleus can be&#xD;
             performed indirectly by measurement from a line connecting the anterior and posterior&#xD;
             commissures of the brain.&#xD;
&#xD;
         10. Subject is able to communicate sensations during the ExAblate Transcranial procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with unstable cardiac status including:&#xD;
&#xD;
               1. Unstable angina pectoris on medication&#xD;
&#xD;
               2. Subjects with documented myocardial infarction within six months of protocol&#xD;
                  entry&#xD;
&#xD;
               3. Significant congestive heart failure defined with ejection fraction &lt; 40&#xD;
&#xD;
               4. Subjects with unstable ventricular arrhythmias&#xD;
&#xD;
               5. Subjects with atrial arrhythmias that are not rate-controlled&#xD;
&#xD;
          2. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as&#xD;
             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the&#xD;
             following occurring within the preceding 12 month period:&#xD;
&#xD;
               1. Recurrent substance use resulting in a failure to fulfill major role obligations&#xD;
                  at work, school, or home (such as repeated absences or poor work performance&#xD;
                  related to substance use; substance-related absences, suspensions, or expulsions&#xD;
                  from school; or neglect of children or household).&#xD;
&#xD;
               2. Recurrent substance use in situations in which it is physically hazardous (such&#xD;
                  as driving an automobile or operating a machine when impaired by substance use)&#xD;
&#xD;
               3. Recurrent substance-related legal problems (such as arrests for substance related&#xD;
                  disorderly conduct)&#xD;
&#xD;
               4. Continued substance use despite having persistent or recurrent social or&#xD;
                  interpersonal problems caused or exacerbated by the effects of the substance (for&#xD;
                  example, arguments with spouse about consequences of intoxication and physical&#xD;
                  fights).&#xD;
&#xD;
          3. Severe hypertension (diastolic BP &gt; 100 on medication)&#xD;
&#xD;
          4. Subjects with standard contraindications for MR imaging such as non-MRI compatible&#xD;
             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#xD;
&#xD;
          5. Significant claustrophobia that cannot be managed with mild medication.&#xD;
&#xD;
          6. Current medical condition resulting in abnormal bleeding and/or coagulopathy&#xD;
&#xD;
          7. Patient with severely impaired renal function with estimated glomerular filtration&#xD;
             rate &lt;30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or&#xD;
             who is on dialysis;&#xD;
&#xD;
          8. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within&#xD;
             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage&#xD;
             (e.g. Avastin) within one month of focused ultrasound procedure&#xD;
&#xD;
          9. Subjects with risk factors for intraoperative or postoperative bleeding as indicated&#xD;
             by: platelet count less than 100,000 per cubic millimeter, a documented clinical&#xD;
             coagulopathy, or INR coagulation studies exceeding the institution's laboratory&#xD;
             standard&#xD;
&#xD;
         10. History of intracranial hemorrhage&#xD;
&#xD;
         11. History of multiple strokes, or a stroke within past 6 months&#xD;
&#xD;
         12. Subject who weigh more than the upper weight limit of the table or subjects who will&#xD;
             not fit into the MR scanner&#xD;
&#xD;
         13. Subjects who are not able or willing to tolerate the required prolonged stationary&#xD;
             supine position during treatment.&#xD;
&#xD;
         14. Are participating or have participated in another clinical trial in the last 30 days&#xD;
&#xD;
         15. Subjects unable to communicate with the investigator and staff.&#xD;
&#xD;
         16. Presence of central neurodegenerative disease, including but not limited to&#xD;
             Parkinson-plus syndromes, suspected on neurological examination. These include:&#xD;
             multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia&#xD;
             with Lewy bodies, and Alzheimer's disease.&#xD;
&#xD;
         17. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic&#xD;
             medications.&#xD;
&#xD;
         18. Presence of significant cognitive impairment as determined with a score ≤ 24 on the&#xD;
             Mini Mental Status Examination (MMSE)&#xD;
&#xD;
         19. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms,&#xD;
             psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable,&#xD;
             chronic anxiety or depressive disorders may be included provided their medications&#xD;
             have been stable for at least 60 days prior to study entry and if deemed appropriately&#xD;
             managed by the site neuropsychologist&#xD;
&#xD;
         20. Subjects with significant depression as determined following a comprehensive&#xD;
             assessment by a neuropsychologist. Significant depression is being defined&#xD;
             quantitatively as a score of greater than 14 on the Beck Depression Inventory.&#xD;
&#xD;
         21. Legal incapacity or limited legal capacity as determined by the neuropsychologist&#xD;
&#xD;
         22. Subjects with a history of seizures within the past year&#xD;
&#xD;
         23. Subjects with brain tumors&#xD;
&#xD;
         24. Subjects with intracranial aneurysms requiring treatment or arterial venous&#xD;
             malformations (AVMs) requiring treatment.&#xD;
&#xD;
         25. Any illness that in the investigator's opinion preclude participation in this study.&#xD;
&#xD;
         26. Pregnancy or lactation.&#xD;
&#xD;
         27. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the&#xD;
             basal ganglia&#xD;
&#xD;
         28. Subjects with remarkable atrophy and poor healing capacity of the scalp (&gt; 30% of the&#xD;
             skull area traversed by the sonication pathway) will be excluded from this study&#xD;
&#xD;
         29. Subjects who have an Overall Skull Density Ratio of 0.30 (±0.05) or less as calculated&#xD;
             from the screening CT.&#xD;
&#xD;
               -  It should be noted that for those candidates whose SDR ratio score is within the&#xD;
                  standard deviation, full technical assessment should be performed and reviewed by&#xD;
                  study investigator with the support of the sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bernstein</last_name>
    <role>Study Director</role>
    <affiliation>InSightec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maritn Bernstein</last_name>
    <phone>+97248131268</phone>
    <email>martinb@insightec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Provincial Peoples Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Bai, MD</last_name>
      <phone>+86-18838277756</phone>
      <email>zhaodedao@sina.com</email>
    </contact>
    <investigator>
      <last_name>Meiyun Wang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etsuko Shimizu</last_name>
      <phone>+81-466-35-1177</phone>
      <email>shimizu@mirai-iryo.com</email>
    </contact>
    <investigator>
      <last_name>Tetsumasa Kamei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hisashi Ito, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shigeru Fukutake, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kazuaki Yamamoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

